PBC-PSC overlapping syndrome is a dubious disease in the field of autoimmune and rheumatic immunity, with clinical performance being complex and often involving multi-system fatigue. Early identification and standardized diagnosis are critical to improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in linking teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment plans for the treatment and management of PBC-PSC overlapping syndrome require individual development, usually including multidimensional management, including pharmacotherapy, rehabilitation interventions, and regular follow-up. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune disorders that were previously difficult to treat have been significantly improved.
Treatment requires close monitoring of therapeutic efficacy and adverse reactions, adapting to timely schemes according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of PBC-PSC overlapping syndrome. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.